Optinose

Optinose company information, Employees & Contact Information

Explore related pages

Optinose email format Optinose management contacts

Related company profiles:

As of May 21, 2025, Optinose was acquired by Paratek Pharmaceuticals. Please follow @Paratek for the latest updates and information about the acquisition.

Company Details

Employees
130
Address
1020 Stony Hill Road, Suite 300,norway
Phone
267-364-3500
Email
in****@****nose.no
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
optinose.com
Keywords
Manager jobs.
HQ
Yardley, PA
Competitors
AbbVie, Sanofi, Incyte, Amgen, AstraZeneca, Ascendis Pharma, Paratek Pharmaceuticals, Vanda Pharmaceuticals, Madrigal Pharmaceuticals, ARS Pharmaceuticals, Inc..
Looking for a particular Optinose employee's phone or email?

Optinose Questions

News

Optinose Cancels Earnings Conference Call Following Acquisition Agreement with Paratek Pharmaceuticals - Nasdaq

Optinose Cancels Earnings Conference Call Following Acquisition Agreement with Paratek Pharmaceuticals Nasdaq

Optinose Announces 1-for-15 Reverse Stock Split - GlobeNewswire

Optinose Announces 1-for-15 Reverse Stock Split GlobeNewswire

Optinose Reports Preliminary Q4 2024 XHANCE Net Revenue of $22.4 Million, Indicating Continued Growth - Quiver Quantitative

Optinose Reports Preliminary Q4 2024 XHANCE Net Revenue of $22.4 Million, Indicating Continued Growth Quiver Quantitative

Optinose, Inc. Announces 1-for-15 Reverse Stock Split Effective December 30, 2024 - Nasdaq

Optinose, Inc. Announces 1-for-15 Reverse Stock Split Effective December 30, 2024 Nasdaq

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million - Yahoo Finance

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million Yahoo Finance

Optinose Appoints Terry Kohler as Chief Financial Officer - citybiz

Optinose Appoints Terry Kohler as Chief Financial Officer citybiz

Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M - Fierce Pharma

Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M Fierce Pharma

Document - SEC.gov

Document SEC.gov

Fluticasone Propionate (XHANCE) Receives FDA Approval for Chronic Rhinosinusitis - HCPLive

Fluticasone Propionate (XHANCE) Receives FDA Approval for Chronic Rhinosinusitis HCPLive

Akin Advised Pharmakon in its Debt Financing for Optinose’s Sale to Paratek Pharmaceuticals - akingump.com

Akin Advised Pharmakon in its Debt Financing for Optinose’s Sale to Paratek Pharmaceuticals akingump.com

Paratek expands commercial portfolio with acquisition of Optinose - Pharmaceutical Technology

Paratek expands commercial portfolio with acquisition of Optinose Pharmaceutical Technology

Optinose Announces $55 Million Registered Direct Offering - GlobeNewswire

Optinose Announces $55 Million Registered Direct Offering GlobeNewswire

Expanded Access to XHANCE with Addition to National Commercial Formularies - Yahoo Finance

Expanded Access to XHANCE with Addition to National Commercial Formularies Yahoo Finance

Optinose Appoints Paul Spence as Chief Commercial Officer - citybiz

Optinose Appoints Paul Spence as Chief Commercial Officer citybiz

Reacting to the FDA Approval of Fluticasone Propionate Nasal Spray, with James Palmer, MD - HCPLive

Reacting to the FDA Approval of Fluticasone Propionate Nasal Spray, with James Palmer, MD HCPLive

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results - GlobeNewswire

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results GlobeNewswire

Optinose Chief Financial Officer Michele Janis to Retire - citybiz

Optinose Chief Financial Officer Michele Janis to Retire citybiz

XHANCE Approved by FDA as First and Only Medication - GlobeNewswire

XHANCE Approved by FDA as First and Only Medication GlobeNewswire

Optinose Reports Second Quarter 2022 Financial Results and Operational Updates - citybiz

Optinose Reports Second Quarter 2022 Financial Results and Operational Updates citybiz

Paratek adds chronic rhinosinusitis drug to portfolio with $330M Optinose acquisition - FirstWord Pharma

Paratek adds chronic rhinosinusitis drug to portfolio with $330M Optinose acquisition FirstWord Pharma

Earnings call: OptiNose highlights potential of XHANCE in Q3 2023, explores new commercialization strategies - Investing.com

Earnings call: OptiNose highlights potential of XHANCE in Q3 2023, explores new commercialization strategies Investing.com

Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care - PR Newswire

Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In Stepwise Care PR Newswire

Paratek to buy Optinose for up to $330 million - The Pharma Letter

Paratek to buy Optinose for up to $330 million The Pharma Letter

Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M - BioSpace

Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M BioSpace

Optinose Acquired by Paratek Pharmaceuticals for $330 Million - TipRanks

Optinose Acquired by Paratek Pharmaceuticals for $330 Million TipRanks

Drug-Device Combo Looks Promising for Chronic Sinusitis - Medical Professionals Reference

Drug-Device Combo Looks Promising for Chronic Sinusitis Medical Professionals Reference

Achieving Self Sufficiency In Data Collection For Optinose - Clinical Leader

Achieving Self Sufficiency In Data Collection For Optinose Clinical Leader

Further Upside For OptiNose, Inc. (NASDAQ:OPTN) Shares Could Introduce Price Risks After 56% Bounce - simplywall.st

Further Upside For OptiNose, Inc. (NASDAQ:OPTN) Shares Could Introduce Price Risks After 56% Bounce simplywall.st

OptiNose-Paratek Merger: What Shareholders Need to Know (OPTN, PRTK) - tradingcalendar.com

OptiNose-Paratek Merger: What Shareholders Need to Know (OPTN, PRTK) tradingcalendar.com

Bucks County's Optinose wins FDA approval for wider use of flagship product - The Business Journals

Bucks County's Optinose wins FDA approval for wider use of flagship product The Business Journals

Optinose CEO and other top executives exit after company's acquisition by Paratek - The Business Journals

Optinose CEO and other top executives exit after company's acquisition by Paratek The Business Journals

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays - PR Newswire

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays PR Newswire

New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day - PR Newswire

New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day PR Newswire

And, exhale: Relief for Optinose as delivery system hits primary endpoints in chronic sinusitis phase 3 - Fierce Pharma

And, exhale: Relief for Optinose as delivery system hits primary endpoints in chronic sinusitis phase 3 Fierce Pharma

OptiNose (OPTN) Stock Price, News & Analysis - MarketBeat

OptiNose (OPTN) Stock Price, News & Analysis MarketBeat

Can a radical new device make an old steroid into a big seller? For OptiNose's Xhance, analysts say yes - Fierce Pharma

Can a radical new device make an old steroid into a big seller? For OptiNose's Xhance, analysts say yes Fierce Pharma

Peter Miller of Optinose: To Work Here, Win the ‘Nice’ Vote (Published 2015) - The New York Times

Peter Miller of Optinose: To Work Here, Win the ‘Nice’ Vote (Published 2015) The New York Times

OptiNose’s Inventive Nasal Spray Device - Healthcare Packaging

OptiNose’s Inventive Nasal Spray Device Healthcare Packaging

With FDA filing in sight, OptiNose preps novel nasal-spray gadget for 2017 rollout - Fierce Pharma

With FDA filing in sight, OptiNose preps novel nasal-spray gadget for 2017 rollout Fierce Pharma

Companies like Optinose

AbbVie logo - Similar company to Optinose

Abbvie

57.01K
Vanda Pharmaceuticals logo - Similar company to Optinose

Vanda Pharmaceuticals

544
ARS Pharmaceuticals, Inc. logo - Similar company to Optinose

Ars Pharmaceuticals,...

163
Sanofi logo - Similar company to Optinose

Sanofi

88.33K
Madrigal Pharmaceuticals logo - Similar company to Optinose

Madrigal Pharmaceuti...

755
AstraZeneca logo - Similar company to Optinose

Astrazeneca

78.61K
Ascendis Pharma logo - Similar company to Optinose

Ascendis Pharma

1.19K
Paratek Pharmaceuticals logo - Similar company to Optinose

Paratek Pharmaceuticals

350
Amgen logo - Similar company to Optinose

Amgen

35.77K
Incyte logo - Similar company to Optinose

Incyte

3.20K

Top Optinose Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant